{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:27:30Z","timestamp":1781954850417,"version":"3.54.5"},"reference-count":23,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Salvage re-irradiation (rRT) for patients with locoregionally recurrent head and neck cancer (rHNC) remains challenging. A retrospective analysis was performed on 49 patients who received rRT between 2011 and 2018. The co-primary endpoint of the study was 2-year freedom from cancer recurrence rate (FCRR) and overall survival (OS), and secondary endpoints were 2-year disease-free survival (DFS), local failure (LF), regional failure (RF), distant metastases (DM), and RTOG grade 3 \u2265 late toxicities. Adjuvant and definitive rRT were delivered to 22 and 27 patients, respectively. A total of 91% of patients were managed with conventional re-RT and 71% of patients received concurrent chemotherapy. The median follow-up after rRT was 30 months. The 2-year FCRR, OS, DFS, LF, RF, and DM were 64%, 51%, 28%, 32%, 9%, and 39% respectively. MVA showed that poor performance status (PS: 1\u20132 vs. 0) and age &gt; 52 years were predictive of worse OS. In comparison, poor PS (1\u20132 vs. 0) and total dose of rRT &lt; 60 Gy were predictive of worse DFS. Late RTOG toxicity of grade 3 \u2265 was reported in nine (18.3%) patients. FCRR at 2 years after salvage rRT for rHNC was higher than other traditional endpoints and could be an important endpoint to be included in future rRT studies. rRT for rHNC at our cohort was relatively successful, with a manageable level of late severe toxicity. Replacing this approach in other developing countries is a viable option.<\/jats:p>","DOI":"10.3390\/jcm12082979","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T02:01:11Z","timestamp":1681956071000},"page":"2979","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate"],"prefix":"10.3390","volume":"12","author":[{"given":"Issa","family":"Mohamad","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Abu Hejleh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sania","family":"Abdelqader","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wahbeh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-8622","authenticated-orcid":false,"given":"Ayat","family":"Taqash","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelatif","family":"Almousa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Mayta","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-6789","authenticated-orcid":false,"given":"Fawzi","family":"Abuhijla","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5397-6267","authenticated-orcid":false,"given":"Ramiz","family":"Abu-Hijlih","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-6532","authenticated-orcid":false,"given":"Tariq","family":"Hussein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisam","family":"Al-Gargaz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Ghatasheh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, King Hussein Cancer Center, Amman 11942, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/annonc\/mdh308","article-title":"Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience","volume":"15","author":"Brockstein","year":"2004","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14737140.2020.1708197","article-title":"Palliative chemotherapy in head and neck cancer: Balancing between beneficial and adverse effects","volume":"20","author":"Rajendra","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1586\/era.09.113","article-title":"Cetuximab in metastatic or recurrent head and neck cancer: The EXTREME trial","volume":"9","author":"Rivera","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1007\/s00405-016-4093-3","article-title":"Management of recurrent head and neck cancer: Variables related to salvage surgery","volume":"273","author":"Esteller","year":"2016","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdy018","article-title":"Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck","volume":"29","author":"Awan","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctro.2021.03.004","article-title":"Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study","volume":"28","author":"Balermpas","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2017.04.017","article-title":"A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer","volume":"100","author":"Vargo","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.14338\/IJPT-20-00065.1","article-title":"Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience","volume":"8","author":"Gunn","year":"2021","journal-title":"Int. J. Part Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hed.20697","article-title":"Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck","volume":"30","author":"Spencer","year":"2008","journal-title":"Head Neck"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1200\/JCO.2006.07.9194","article-title":"Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Protocol 9911","volume":"25","author":"Langer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2017.06.012","article-title":"Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative","volume":"100","author":"Ward","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2022.03.034","article-title":"Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria","volume":"113","author":"Ward","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.21037\/cco.2017.07.01","article-title":"Re-irradiation with stereotactic body radiation therapy (SBRT)","volume":"6","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11864-021-00936-y","article-title":"Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: A Review of the Contemporary Evidence","volume":"23","author":"Kreinbrink","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_17","first-page":"1031","article-title":"Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707)","volume":"52","author":"Lee","year":"2020","journal-title":"Orig. Artic. Cancer Res. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3857\/roj.2021.00640","article-title":"Re-irradiation for recurrent or second primary head and neck cancer","volume":"39","author":"Lee","year":"2021","journal-title":"Radiat. Oncol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2008.04.021","article-title":"IMRT Reirradiation of Head and Neck Cancer-Disease Control and Morbidity Outcomes","volume":"73","author":"Sulman","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00066-020-01647-3","article-title":"Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area","volume":"197","author":"Boustani","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clon.2011.11.010","article-title":"Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy","volume":"24","author":"Han","year":"2012","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109380","DOI":"10.1016\/j.radonc.2022.10.007","article-title":"Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer\u2014Results of a large multicenter analysis","volume":"181","author":"Roesch","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.oraloncology.2019.01.022","article-title":"A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck","volume":"90","author":"Ward","year":"2019","journal-title":"Oral Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2979\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:19:10Z","timestamp":1760123950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12082979"],"URL":"https:\/\/doi.org\/10.3390\/jcm12082979","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}